The Functional -765G→C Polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  de Vries, Hilbert S ^a   te Morsche, Rene H M ^a   van Oijen, Martijn G H ^a,b   Nagtegaal, Iris D ^a   Peters, Wilbert H M ^a   de Jong, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GENOMIC DNA; PTGS2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; FEMALE; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; DISEASE COURSE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PHENOTYPE; RISK; RISK FACTOR;

ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 78649684953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015011     Document Type: Article

References (40)

1. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-34.
2. Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577-94.
3. Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb Journal 18: 790-804.
4. Martin GR, Wallace JL (2006) Gastrointestinal inflammation: A central component of mucosal defense and repair. Exp Biol Med 231: 130-137.
5. Fornai M, Antonioli L, Colucci R, Bernardini N, Ghisu N, et al. (2010) Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. Pharmacol Therapeut 125: 62-78.
6. Trifan OC, Hla T (2003) Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7: 207-222.
7. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, et al. (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115: 297-306.
8. Roberts PJ, Morgan K, Miller R, Hunter JO, Middleton SJ (2001) Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 48: 468-472.
9. Tabernero A, Reimund JM, Chasserot S, Muller CD, Andriantsitohaina R (2003) Cyclooxygenase-2 expression and role of vasoconstrictor prostanoids in small mesenteric arteries from patients with Crohn's disease. Circulation 107: 1407-1410.
10. Hendel J, Nielsen OH (1997) Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 92: 1170-1173.
11. Wallace JL (2006) COX-2: A pivotal enzyme in mucosal protection and resolution of inflammation. Thescientificworldjournal 6: 577-588.
12. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, et al. (2004) The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 10: 352-356.
13. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, et al. (2006) Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol H 4: 196-202.
14. Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, et al. (2004) Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharm Ther 19: 755-764.
15. Zhang XM, Miao XP, Tan W, Ning BT, Liu ZH, et al. (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129: 565-576.
16. Ostergaard M, Ernst A, Labouriau R, Dagiliene E, Krarup HB, et al. (2009) Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand J Gastroentero 44: 65-73.
17. Cox DG, Crusius JB, Peeters PH, Bueno-de-Mesquita HB, Pena AS, et al. (2005) Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J Gastroenterol 2005 11: 6003-6008.
18. Podolsky DK (2002) Inflammatory bowel disease. New Engl J Med 347: 417-429.
19. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, et al. (2000) A simple classification of Crohn's disease: Report of the Working Party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis 6: 8-15.
20. Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19: 5A-36A.
21. Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, van de Pol A, et al. (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29: 19-24.
22. Peters WHM, Lacko M, Morsche RHMT, Voogd AC, Ophuis MBO, et al. (2009) Cox-2 Polymorphisms and the Risk for Head and Neck Cancer in White Patients. Head Neck 31: 938-943.
23. Rudock ME, Liu Y, Ziegier JT, Allen SG, Lehtinen AB, et al. (2009) Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study. Atherosclerosis 203: 459-465.
24. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, et al. (2002) Common promoter variant in cyclooxygenase-2 represses gene expression - Evidence of role in acute-phase inflammatory response. Arterioscl Throm Vas 22: 1631-1636.
25. Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, et al. (2009) Influence of Cyclooxygenase-2 (COX-2) Gene Promoter Polymorphism-765 on Graft Loss After Renal Transplantation. Am J Transplant 9: 2752-2757.
26. Zhao D, Xu DK, Zhang XM, Wang L, Tan W, et al. (2009) Interaction of Cyclooxygenase-2 Variants and Smoking in Pancreatic Cancer: A Possible Role of Nucleophosmin. Gastroenterology 136: 1659-1668.
27. Mariani F, Sena P, Marzona L, Riccio M, Fano R, et al. (2009) Cyclooxygenase-and Hypoxia-Inducible Factor-1 alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Lett 279: 221-229.
28. Szczeklik W, Sanak M, Szczeklik A (2004) Functional effects and gender association of COX-2 gene polymorphism G(2765)C in bronchial asthma. J Allergy Clin Immun 114: 248-253.
29. Sanak M, Szczeklik W, Szczeklik A (2005) Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immun 116: 221-223.
30. Carty E, De Brabander M, Feakins RM, Rampton DS (2000) Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 46: 487-492.
31. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, et al. (2007) The proinflammatory effect of prostaglandin E-2 in experimental inflammatory bowel disease is mediated through the IL-23 -. IL-17 axis. Journal Immunol 178: 8138-8147.
32. Jiang GL, Nieves A, Im WB, Old DW, Dinh DT, et al. (2007) The prevention of colitis by E prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther 320: 22-8.
33. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, et al. (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206: 535-548.
34. Andersen V, Nimmo E, Krarup HB, Drummond H, Christensen J, Ho GT, et al. Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study. Inflamm Bowel Dis. In press.
35. Hugot JP, Zaccaria I, Cavanaugh J, Yang HY, Vermeire S, et al. (2007) Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 102: 1259-1267.
36. Hasegawa K, Ichikawa W, Fujita T, Ohno R, Okusa T, et al. (2001) Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 37: 1469-1474.
37. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, et al. (2000) The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 157: 737-745.
38. Hoff JH, te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM, et al. (2009) COX-2 polymorphisms 2765GRC and 21195ARG and colorectal cancer risk. World J Gastroenterol 15: 4561-4565.
39. Tan W, Wu JX, Zhang XM, Guo YL, Liu JN, et al. (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28: 1197-1201.
40. Westbrook AM, Szakmary A, Schiestl RH (2010) Mechanisms of intestinal inflammation and development of associated cancers: Lessons learned from mouse models. Mutat Res 705: 40-59.